Treatment of benign prostate hyperplasia using the Rezum® water vapor therapy system: Results at one year

Alegorides, C.; Fourmarier, M.; Eghazarian, C.; Lebdai, Souhil; Chevrot, A.; Droupy, S.

doi:10.1016/j.purol.2020.05.004

Cited by 31 publications

(28 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and four studies [11][12][13][14][15][16][17][18][19]26 and 65%, respectively), and two studies [11][12][13][14][15][16]26 reported a significant increase at the 12-month follow-up (median percent improvement in MSHQ-bother 38%).…”

Section: Efficacymentioning

confidence: 96%

“…After removing duplicates, 461 records were screened for eligibility based on title and abstract, of which 36 records were selected for full-text review. Twenty-five articles were included in the systematic review, of which six were from an RCT, [11][12][13][14][15][16] six were from five prospective studies [17][18][19][20][21][22] in which two articles were of the same study 18,19 and one article was of the crossover arm from the RCT, 17 eleven were from retrospective studies, [23][24][25][26][27][28][29][30] and two were from case series 31,32 (Figure 1).…”

Section: Study Selectionmentioning

confidence: 99%

“…McVary et al 27 Baboudjian et al 34 Bassily et al 35 Besides the pilot study by Dixon et al 18,19 all the studies were conducted in the United States before 2020. [11][12][13][14][15][16][17]23,24 Recently, however, more studies have been conducted in different countries including France, 26,30,34 United Kingdom, 21,31 Italy, 22 and Ireland. 32 Sample size and patient follow-up in each study ranged from 10 to 255 patients (median 65 patients) and 1 to 60 months (median 12 months), respectively ( 2).…”

Section: Study Patient and Procedural Characteristicsmentioning

confidence: 99%

“…Mean procedure time ranged from 4.4 to 13.0 minutes (median 7.0 minutes). Out of the 19 studies, 11-35 14 [11][12][13][14][15][16][18][19][20][21][22][24][25][26][27][28][29][30][31][32][33][34][35] reported postoperative urinary catheter rates which ranged from 65% to 100%, with 13 studies 21,22,[25][26][27][28][29][30][31][32][33][34][35] having a rate of 100%. The mean number of days patients were catheterized postoperatively ranged from 3.0 to 32.2 days, with the upper limit reserved for those who had urinary retention at baseline (Table 3).…”

Section: Study Patient and Procedural Characteristicsmentioning

confidence: 99%

“…When compared to baseline, IPSS, QoL, and Qmax significantly improved as early as 1 month posttreatment (median percent improvements 31%, 24%, and 34%, respectively) and remained (median 51%), 32% to 86% (median 51%), and 32% to 130% (median 66%), respectively. Out of the seven studies [11][12][13][14][15][16][17][18][19]21,25,26,33 that evaluated PVR from baseline to 3, 6 to 7.2, and 12 months, only two studies 21,26 found it to be significantly improved at all three follow-ups (median percent improvements 54%, 56%, and 57%, respectively) (Table 4).…”

Section: Efficacymentioning

confidence: 99%

See 4 more Smart Citations

Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review

Babar

Loloi

Tang

et al. 2022

LUTS

View full text Add to dashboard Cite

Water vapor thermal therapy (Rezum) is a novel, minimally invasive surgical technology used to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The objective of this systematic review is to evaluate the latest efficacy and safety profile of Rezum in patients with LUTS secondary to BPH. PubMed/MEDLINE and the Cochrane Library databases were systematically searched, in accordance with the PRISMA statement, for relevant articles in the English language till 1 August 2021. Randomized and nonrandomized studies that evaluated urinary outcomes and/or adverse events were deemed eligible. Nineteen studies (N = 1942), published in 25 articles, were included. International Prostate Symptom Score (IPSS), quality of life (QoL), and maximum urinary flow rate (Qmax) significantly improved as early as 1 month postoperatively and remained durable for up to 5 years. Significant median percent improvements in IPSS, QoL, and Qmax at 3 months were 51%, 51%, and 66%, respectively. Patients with obstructive median lobes, large prostates (>80 g), small prostates (<30 g), and urinary retention also experienced significant relief in LUTS, with 83% of urinary retention patients becoming catheter independent at a median of 14 days. Most adverse events were transient and nonserious and occurred in 0% to 76% of patients (median 29%), with de novo erectile dysfunction rates ranging between 0% and 3.1%. Surgical retreatment rate ranged between 4.4% and 7.5% at 5 years postoperatively. Rezum provides durable improvements in symptoms, irrespective of prostate volume and urinary retention status, and has low rates of sexual dysfunction.

show abstract

Section: Efficacymentioning

confidence: 96%

Section: Study Selectionmentioning

confidence: 99%

Section: Study Patient and Procedural Characteristicsmentioning

confidence: 99%

Section: Study Patient and Procedural Characteristicsmentioning

confidence: 99%

Section: Efficacymentioning

confidence: 99%

See 3 more Smart Citations

Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review

Babar

Loloi

Tang

et al. 2022

LUTS

View full text Add to dashboard Cite

show abstract

Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population

et al. 2023

View full text Add to dashboard Cite

Background: The Rezum System (Rezum) represents a novel, minimally invasive surgical therapy used to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). We evaluated the safety and efficacy of Rezum in patients with mild, moderate, or severe LUTS. Methods: A single office, retrospective study was conducted on patients from a multiethnic population treated with Rezum between 2017 and 2019. Patients were categorized into three cohorts based on baseline International Prostate Symptom Score (IPSS) LUTS severity: mild LUTS (IPSS ≤ 7), moderate LUTS (IPSS 8-19), or severe LUTS (IPSS ≥ 20) cohorts. Outcome measures, including IPSS, quality of life (QoL), maximum urinary flow rate (Qmax), postvoid residual (PVR), BPH medication usage, and adverse events (AEs) were collected and analyzed at baseline, 1-, 3-, 6-, and/or 12-months postoperatively.Results: A total of 238 patients were included: 33 with mild LUTS, 109 with moderate LUTS, and 96 with severe LUTS. At 1-month follow-up, the moderate and severe LUTS cohorts saw significant improvements in IPSS (moderate LUTS: −3.0

show abstract

Water vapor thermal therapy of lower urinary tract symptoms due to benign prostatic obstruction: efficacy and safety analysis of a real-world cohort of 211 patients

et al. 2023

View full text Add to dashboard Cite

Purpose This study assessed the efficacy, safety and durability outcomes of water vapor thermal therapy with Rezum in a real-world cohort of patients with lower urinary tract symptoms due to benign prostate obstruction. Methods Consecutive, unselected patients undergoing Rezum treatment between January 2014 and August 2022 were candidates for this pragmatic, observational, longitudinal, single-center cohort study. Pre- and perioperative data were descriptively summarized. The primary outcome was surgical efficacy, determined by International Prostate Symptom Score (IPSS), Quality of Life (QoL) Score, maximum urinary flow rate (Qmax), post-void residual (PVR) volume and prostate volume (PV) at baseline, 2 months, 6 months, 1 year, 2 years, and > 2 years. Results A total of 211 patients were enrolled for analysis. Overall, catheter removal was successful in 92.4% of patients after a median of 5 days. A preoperative catheter and the presence of a median lobe increased the risk of unsuccessful catheter removal. In total, 5.7% of patients were reoperated after a median of 407 days. Comparing baseline to the longest median follow-up, the postoperative IPSS decreased significantly by 65.7%, the QoL Score declined by 66.7% (both until a maximum median of 4.5 years) and Qmax improved by 66.7% (until 3.9 years). Post-void residual volume and PV were reduced by 85.7% (3.7 years) and 47% (4.0 years), respectively. Clavien–Dindo complication ≤ II occurred in 11.8%. Conclusion Rezum is a safe minimally invasive treatment option in a real-world patient cohort with a beneficial improvement of micturition symptoms and voiding function during follow-up.

show abstract

Treatment of benign prostate hyperplasia using the Rezum® water vapor therapy system: Results at one year

Cited by 31 publications

References 16 publications

Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review

Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review

Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population

Water vapor thermal therapy of lower urinary tract symptoms due to benign prostatic obstruction: efficacy and safety analysis of a real-world cohort of 211 patients

Contact Info

Product

Resources

About